FAS and acute leukemia: Thus, As2 yields similar results in sensitizing leukemia cells to chemotherapy, as, for instance, small-molecule XIAP inhibitors that showed results against acute leukemia cells with Bcl-2-mediated resistance, synergizing with TRAIL (TNF-related apoptosis-inducing ligand) or Fas activation [65,66].